PRECISION BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.67 USD | +1.04% |
|
-4.26% | -11.69% |
Presenter SpeechCassie Gorsuch (Executives)Hello, everyone, and welcome to Precision BioScienc...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision. ARCUS particularly generates defined outcomes due to predominant repair using homology directed repair (HDR) as opposed to non-homologous end joining (NHEJ). The Companyâs in vivo gene editing programs include PBGENE-HBV, PBGENE-PMM, PBGENE-NVS, PBGENE-DMD, PBGENE-LL2, PBGENE-LL3 and iECURE-OTC. PBGENE-HBV program is designed for the potential treatment of chronic hepatitis B virus (HBV). The Company is pursuing development of PBGENE-PMM as a potential opportunity for treatment of m.3243 associated primary mitochondrial myopathy (PMM).
Calendar
14/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
9.67
USD
Average target price
33
USD
Spread / Average Target
+241.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.69% | 66.97M | |
| +23.13% | 46.93B | |
| +36.95% | 39.08B | |
| -8.73% | 38.48B | |
| +28.09% | 31.01B | |
| -12.26% | 26.14B | |
| +10.57% | 25.88B | |
| +32.23% | 12.53B | |
| -6.56% | 11.36B | |
| -12.56% | 10.65B |
- Stock Market
- Equities
- DTIL Stock
- News Precision BioSciences, Inc.
- Transcript : Precision BioSciences, Inc. - Special Call
